In line with this, a recent study demonstrated that Notch3 signaling promotes PD-L1 overexpression in breast cancer cells, and specific Notch3 silencing results in PD-L1 downregulation, providing a novel strategy for anti-PD-L1 combination therapies [164]. Here, NOTCH3 is linked to breast cancer.